Abstract:Background: Loss-of-function mutations in GDF2 /BMP9 are found in heritable pulmonary arterial hypertension (PAH), suggesting a protective role, while protective or pathogenic effects are found in experimental PAH studies depending on context. The net contribution of BMP9 in PAH thus remains controversial. Hypothesis: BMP9 regulates the secretome of pulmonary microvascular endothelium (PMVEC) to contribute to pulmonary artery smooth muscle cell (PASMC) phenotype modulation. Methods: We tested recombinant BMP9, BMP9/BMP10 trap ALK1-Fc, and BMP9 neutralizing antibody before and after development of pulmonary hypertension (PH) in distinct experimental models. We analyzed the impact of BMP9 on the PMVEC transcriptome, intersection with human and experimental PAH lung transcriptomes, and tested the impact of EC-derived genes on PASMC phenotype and growth. Results: ALK1-Fc and anti-BMP9 prevented or reversed experimental PH administered before or after onset of experimental PH. Recombinant disulfide-linked BMP9 was not protective in SUGEN/Hypoxia (SU-Hx)- or monocrotaline (MCT)-induced experimental PH, in contrast to previous studies using incompletely disulfide-linked BMP9, suggesting dissociated monomers might function as competitive BMP9 antagonists. Consistent with this interpretation, BMP9 upregulated PMVEC genes associated with pulmonary vascular remodeling in experimental and human PAH including CXCL12, IGFBP4, ET-1, VEGF-A, and PDGF-BB. Stimulation of PMVEC with BMP9 induced a contractile phenotype ( CNN1;TAGLN ) in co-cultured PASMC. Administration of ALK1-Fc or anti-BMP9 attenuated expression of several of these growth factors in SU-Hx PH. In experimental PH ALK1-Fc and ACTRIIA-Fc elicited peripheral edema, a phenotype associated with use of ALK1-Fc in human trials. Conclusions: BMP9 contributes to experimental PH by regulating expression of EC-derived molecules modulating PASMC growth and phenotype. In contrast to broad strategies that inhibit BMP9 and BMP10 associated with HHT mimicry in clinical trials and rodent PH models, treatment with anti-BMP9 was well-tolerated. Selective antagonism of BMP9 represents a potential therapeutic strategy for human PAH.

Crystal structures of BMPRII extracellular domain in binary and ternary receptor complexes with BMP10

Identification of a Novel Mutation in the BMPR2 Gene in a Pulmonary Arterial Hypertension Patient Using Next‐generation Sequencing

Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection

Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy

Histone Arginine Methylation by Prmt5 is Required for Lung Branching Morphogenesis Through Repression of BMP Signaling

Bone Morphogenetic Protein Receptors: Structure, Function and Targeting by Selective Small Molecule Kinase Inhibitors

Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms

Type II BMP and activin receptors BMPR2 and ACVR2A share a conserved mode of growth factor recognition

Abstract 16991: Rare Variants in BMP10 Confer Risk of Pulmonary Arterial Hypertension

Molecular basis of interchain disulfide-bond formation in BMP-9 and BMP-10

Molecular Recognition in Bone Morphogenetic Protein (bmp)/receptor Interaction

Functional characterization of bone morphogenetic protein binding sites and Smad1/5 activation in human vascular cells.

Expression of Mutant BMPR-II in Pulmonary Endothelial Cells Promotes Apoptosis and a Release of Factors That Stimulate Proliferation of Pulmonary Arterial Smooth Muscle Cells

N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding

Effects of Modulating BMP9, BMPR2, and AQP1 on BMP Signaling in Human Pulmonary Microvascular Endothelial Cells

Mutations in Bone Morphogenetic Protein Type II Receptor Cause Dysregulation of Id Gene Expression in Pulmonary Artery Smooth Muscle Cells: Implications for Familial Pulmonary Arterial Hypertension.

Bone morphogenetic protein receptor Ⅱ signaling pathway and pulmonary arterial hypertension:updates and expectations

Abstract 18578: BMP9 Regulates Endothelial Expression of Mediators of Pulmonary Vascular Remodeling

Abstract 108: Mediator 1 Regulation of the BMP / TGF-β Signaling in Endothelium: Implications for Pulmonary Hypertension

Does BMPR2 Mutation Disrupt Pulmonary Vasculogenesis?

BMP Type II Receptor As a Therapeutic Target in Pulmonary Arterial Hypertension.